Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gamez

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Bioorganic & Medicinal Chemistry Letters|February 19, 2013
Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinaseDeborah S Mortensen, John Sapienza, Branden G S Lee, et al.
Molecular Cancer Therapeutics|April 10, 2015
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo CharacterizationDeborah S Mortensen, Kimberly E Fultz, Shuichan Xu, et al.
Nature Communications|November 8, 2023
Single cell spatial analysis reveals inflammatory foci of immature neutrophil and CD8 T cells in COVID-19 lungsPraveen Weeratunga, Laura Denney, Joshua A Bull, et al.
Journal of Medicinal Chemistry|June 24, 2015
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, et al.
Journal of Medicinal Chemistry|June 18, 2015
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Bioorganic & Medicinal Chemistry Letters|February 19, 2013
Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinaseDeborah S Mortensen, John Sapienza, Branden G S Lee, et al.
Molecular Cancer Therapeutics|April 10, 2015
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo CharacterizationDeborah S Mortensen, Kimberly E Fultz, Shuichan Xu, et al.
Nature Communications|November 8, 2023
Single cell spatial analysis reveals inflammatory foci of immature neutrophil and CD8 T cells in COVID-19 lungsPraveen Weeratunga, Laura Denney, Joshua A Bull, et al.
Journal of Medicinal Chemistry|June 24, 2015
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, et al.
Journal of Medicinal Chemistry|June 18, 2015
Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223Deborah S Mortensen, Sophie M Perrin-Ninkovic, Graziella Shevlin, et al.
Pageof 2